Compare Neurocrine Biosciences Inc (NBIX) vs News Corporation Class A Common Stock (NWSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs News Corporation Class A Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $142.16 (market cap $14.36B), while News Corporation Class A Common Stock trades at $29.05 (market cap $16.14B). The key difference: Neurocrine Biosciences Inc and News Corporation Class A Common Stock are close in size by market cap, and News Corporation Class A Common Stock pays a 0.69% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and News Corporation Class A Common Stock for 0 Days on average.
| NBIX | NWSA | |
|---|---|---|
Market Cap | $14.36B | $16.14B |
Volume | 1,237,180 | 4,310,610 |
Sector | Health | Media |
52-Week High | $185.50 | $31.19 |
52-Week Low | $123.10 | $22.40 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $14.37B | $16.96B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About News Corporation Class A Common Stock
News Corporation operates businesses in news and information services, digital real estate, and book publishing. Its brands include Dow Jones, The Wall Street Journal, HarperCollins, Realtor.com, and realestate.com.au.
Read more on NWSA →
